Other Events ·
Ascendis Pharma provided clinical updates for its achondroplasia programs on August 6, 2026
ASNDAscendis Pharma A/S
Ascendis Pharma provided clinical updates for its achondroplasia programs on August 6, 2026. Combination therapy with TransCon CNP and TransCon hGH demonstrated durable growth in the COACH Trial at Week 78, achieving a mean annualized growth velocity exceeding the 97th percentile of average stature children without compromising safety. Monotherapy data from the ApproaCH Trial showed sustained height improvements over 104 weeks. The company completed enrollment for the pivotal reACHin Trial targeting infants and anticipates an EU regulatory decision in Q4 2026. Commercially, YUVIWEL enrollments exceeded 170 patients through June 30, 2026. Ascendis Pharma is a biopharmaceutical company developing therapies for rare diseases using its TransCon technology platform.